Who are we?

FIT, based in the Oxford Science Park and utilising new-generation technologies developed from the collaboration between ISIS and FIT’s existing world-leading auto-injector design team, have developed and launched a new range of needle-safe auto-injectors required for the imminent explosion in the demand for such devices, especially for viscous drugs.

Whilst FITs range of devices can easily cope with any existing medication, the Unique Selling Point of FITs range of products is the patent pending method of drug delivery that means that no force is applied to the vulnerable parts of the syringe, thus eliminating the risk of syringe breakage and fully automated active needle management, completely occulting the needle at all times, meeting all International Needlestick Regulations, whilst delivering every single drop of drug and at the predetermined depth.

Our Chief Designer Kevin Stamp is a leading designer to the Pharmaceutical Industry, having designed amongst others, the ASI auto-injector and needle-free injector for Medical House Limited. Nobody in the world knows more about auto-injectors.

He also has designed other medical systems and Implants for major Orthopaedic Companies such as J&J, DePuy, Biomet, Zimmer, Ortho Solutions and Stratec.

Our CEO Dr Paul Whyte is a seasoned business development professional with experience in senior leadership roles spanning both large pharmaceutical and small start-up biotechnology companies. Paul shares the excitement and determination of the founding directors to build FIT into the world leader in development of new and novel auto-injector technologies to capitalise on the increasing market opportunity. Paul is a Senior Consultant at Isis Enterprise.

Paul has experience in commercial leadership roles spanning the pharmaceutical, academic and emerging technology environments from partnering late stage pharmaceutical products to exploiting innovative emerging products and technologies. Prior to joining FIT, Paul was responsible for leading the commercial development and partnering of therapeutic medicines at Evolutec plc as Director of Business Development and prior to this for partnering Avidex Ltd’s (Medigene’s) cancer and inflammatory therapies and therapeutic discovery platform.

Paul also spent several years at Cancer Research Technology (CRT) in a commercial role during its rapid organisational growth where he was instrumental in forming a joint venture company - Cancer Therapeutics Limited, with Antisoma plc to develop a late stage cancer therapy, commercialising CRTs portfolio based around the Muc-1 cancer antigen and executing numerous licence transactions.

In his early career Paul worked on cancer diagnostics at Zeneca Diagnostics, undertook vaccine research and development at Pierre Fabre Medicament and was part of a small molecule drug discovery team at Astra Zeneca. Paul has an honours degree from Warwick University, a PhD in immunology and an MBA.

Mr Bob Sharp is a director of FIT and an Orthopaedic Consultant at the world-renowned Nuffield Orthopaedic Centre in Oxford, where he leads the Department Research Team. In addition to FIT he is a director of MTL Ltd and nonexecutive Director of The PJA Ltd . He is a former director of OxMed Ltd , sits on the Medical Advisory Committee to the BHA, is on the panel of experts of Gehrson Lehmann and has been an Orthopaedic Expert for several City Institutions. He has Industry links to several Orthopaedic Companies and has designed and brought to market several Orthopaedic devices. He is the co-lead clinician on the NJR proposal for Ankle Replacements and is the BOFAS representative to NICE on new technology in Orthopaedics.

Mr Eliot Clare & Mr Rupert Hosking are directors of FIT and are Managing Directors of a medium sized UK Orthopaedic Company, Ortho Solutions Ltd. that has rapidly become the UK’s fourth largest Orthopaedic Company. Product. Innovation and pre-packed sterile implants differentiate Ortho Solutions from its competitors. Their vast experience in business management and marketing is complemented by a long track record of successful regulatory approval of medical devices in the UK and US.